Business Context and Reporting Period
This Form 8-K was filed by Biorestorative Therapies, Inc. on December 2, 2019, reporting events occurring between November 29, 2019, and December 6, 2019. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial activity reported is the conversion of debt to equity:
- Debt Converted: $88,141 (inclusive of accrued and unpaid interest).
- Shares Issued: 6,451,896 shares of common stock.
- Liquidity Impact: The transaction reduced outstanding indebtedness without a cash outflow.
Material Changes
The primary material change is the reduction of the company's debt load by $88,141 through the issuance of common stock. This transaction increased the total number of outstanding shares by 6,451,896. The filing does not provide comparative data to prior periods for revenue or operating metrics.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction. The company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for the exemption of this unregistered sale of equity securities. The company represented that investors were accredited and had access to prior financial reports (10-K and 10-Q filings).
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the remaining outstanding indebtedness after the $88,141 conversion.
- Review the company's most recent 10-Q (ended September 30, 2019) for current cash position and liquidity status.
- Check for any subsequent filings regarding the status of the 6,451,896 shares issued.